Dutch biotech company VectorY Therapeutics raises one of Europe’s largest private biotech rounds in 2023

VectorY Therapeutics combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. Here are details of VectorY‘s latest funding round :

🚀 Launch

2020

🏭 Industry

Biotechnology

🧠Management

Sander van Deventer (CEO)

💸 Funding & Investors

INVESTMENT (Novembre 2023)€129 million (Series A)
INVESTORS (Novembre 2023)co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund. New and existing investors also participated in the round, including MRL Ventures Fund, Rahway, NJ USA, Insight Partners, ALS Investment Fund, Forbion Ventures, BioGeneration Ventures (BGV) and another known investor.

🎯 Funding purpose

Support the clinical development of VTx-002, its lead vectorized antibody program targeting TDP-43 for ALS treatment.

🌐 Country HQ

The Netherlands (Amsterdam)

Leave a Reply

Your email address will not be published.